Most upside (3 months)

The Most Upside chart above shows the companies potential share price gain (%) (the potential share price increase from the current share to the broker target price)

  Company % change  
  Tertiary Minerals PLC 74,185.71  
  Telit Communications PLC 108.54  
  Benchmark Holdings Plc 100.00  
  Connect Group PLC 78.74  
  Greencore Group PLC 77.36  
  Servelec Group 60.25  
  Shire PLC 56.88  
  Spire Healthcare Group 56.05  
  Pendragon PLC 49.59  
  Lookers PLC 46.87  
  The Gym Group Plc 44.23  
  Low & Bonar PLC 41.77  
  Ibstock Plc 36.20  
  Whitbread PLC 35.14  
  Ladbrokes Coral Group Plc 32.89  

Performance Analysis (6 Months)

The performance analysis chart above provides a detailed breakdown of Buy, Sell and Hold recommendations for the selected bank or stockbroker. To see a full explanation of how to use this chart, please visit the performance analysis explanation page.

Recommendation Summary (3 months)

Berenberg News

  • Broker views: Hotels and oil

    Equity analysts at Berenberg upped their recommendation on Millennium & Copthorne (LON:MLC) to 'hold' (from 'sell') after boosting their earnings estimates following better than expected first...
  • Greggs upgraded by Berenberg

    10 August 2017 | Greggs
    Berenberg has upgraded its recommendation on high street baker Greggs (LON:GRG) to buy from hold saying that it is increasingly confident that the sausage roll to steak bake maker can continue to...
  • Berenberg downgrades NCC

    24 July 2017 | NCC Group
    Berenberg has moved to a sell rating (from hold) on cyber security and risk mitigation services provider NCC Group (LON:NCC), believing the restructuring has now been priced in. The bank...
  • HSBC downgraded by Berenberg

    04 July 2017 | HSBC Holdings
    Berenberg has downgraded its investment rating on banking group HSBC (LON:HSBA) to hold from buy, believing the stock is now fully valued. Nevertheless, analyst James Chappell commented: "HSBC is...
  • GlaxoSmithKline upgraded by Berenberg

    26 May 2017 | GlaxoSmithKline
    Berenberg has upgraded its recommendation on GlaxoSmithKline (LON:GSK) believing long-term value is emerging and that risks are now skewed to the upside at a group level, despite its HIV business,...

Berenberg Notes